The widespread adoption and use of electronic health records and their use to enable learning health systems (LHS) holds great promise to accelerate both evidence-generating medicine (EGM) and evidence-based medicine (EBM), thereby enabling a LHS. In 2016, AMIA convened its 10th annual Policy Invitational to discuss issues key to facilitating the EGM-EBM paradigm at points-of-care (nodes), across organizations (networks), and to ensure viability of this model at scale (sustainability). In this article, we synthesize discussions from the conference and supplements those deliberations with relevant context to inform ongoing policy development. Specifically, we explore and suggest public policies needed to facilitate EGM-EBM activities on a national scale, particularly those policies that can enable and improve clinical and health services research at the point-of-care, accelerate biomedical discovery, and facilitate translation of findings to improve the health of individuals and populations.
INTRODUCTION AND BACKGROUND
As a consequence of the almost universal adoption of electronic health records (EHRs) in the United States (US), "data-driven" healthcare-long considered merely theoretical-is now within reach and holds great promise. 1 However, despite the unprecedented volumes of clinical data generated each day across hospitals, physician offices, urgent care facilities, and neighborhood walk-in clinics, the ability to leverage these data to increase our knowledge of health and disease and drive improvements in care remain overwhelmingly unrealized. 2 The evidence-based medicine (EBM) paradigm has become the bedrock paradigm of clinical decision-making over the last two decades. Today, EBM is being facilitated via the use of EHRs, and its corollary-"evidence-generating medicine" (EGM)-can be operationalized in order to enable the generation of evidence from realworld practice. This approach has the potential to transform a severely limited clinical research system, one that is expensive, inefficient, and incapable of scaling to address the myriad unanswered clinical questions faced by clinicians and patients. 3, 4 EGM is the "systematic incorporation of research and quality improvement considerations into the organization and practice of healthcare in order to advance biomedical science and thereby improve the health of individuals and populations." 5 The EGM paradigm recognizes that clinical care activities are not entirely distinct from research activities and that the generation of evidence is critical to the EBM lifecycle. 6 EGM is therefore an important and necessary element of enabling a learning health system (LHS), one that seeks to systematically learn from each healthcare encounter, facilitate discovery, and advance our collective understanding of effective approaches to healthcare. 7 Increasingly, all health stakeholders have the opportunity-and obligation-to leverage health information technology (IT) systems, and the valuable data they contain, for the development and delivery of new interventions. The success of several current high-impact, high-visibility research initiatives depend on actualizing this evidence cycle. Examples include the All of Us Research Program 8 and Cancer Moonshot initiative, 9 the Health Care Systems Research Collaboratory, 10 and the development of a national system of realworld evidence generation system as pursued by such groups as the US Food & Drug Administration (FDA), Patient-Centered Outcomes Research Institute (PCORI), National Institutes of Health (NIH), and other federal agencies. 11 It was with this environment and motivation in mind that for 2 days in September 2016, AMIA convened its 10th annual AMIA Policy Invitational (API2016) meeting that brought together key thought leaders to discuss informatics issues related to realizing the emerging paradigm of an EBM-EGM cycle to enable the LHS. As further described below, through a series of facilitated group discussions before and during the API, a strategy for realizing the vision of nationally scaled EGM was developed. The emergent framework focused on facilitating: (1) research opportunities at the "point-care" (nodes), (2) research conducted across organizations (networks), and (3) ensuring the ongoing viability of research at regional/national levels (sustainability). This article explores those discussions and findings in more detail and suggests a range of public policies needed to facilitate EGM activities on a national scale. Special attention in paid to those policies that can enable and improve clinical research at the point-ofcare, accelerate biomedical discovery, and enable translation of findings to improve the health of individuals and populations. Below, we synthesize discussion from the meeting and supplement those conversations with relevant context to inform ongoing policy development.
MEETING STRUCTURE
The 2016 AMIA Policy Invitational (API2016) included over 70 participants that were invited based upon experience and research contributions focused at the intersection of care delivery and research. Approximately 80% were AMIA members, with the remaining 20% composed of policy professionals and non-AMIA members from industry, government, professional associations. Attendees were identified by the conference chair and were not paid for their participation. Based upon premeeting deliberations led by a core group of experts that constituted the API2016 planning committee, the 2-day meeting was segmented into three broad levels of abstraction: (1) nodes, (2) networks, and (3) sustainability. Each level was covered in a portion of the meeting that included expert presentations on key topics followed by breakout working group discussions to further explore the topic and its policy implications. The first session focused on how to integrate research at the point-of-care, symbolized as a node. Next, meeting attendees considered issues and policy implications related to conducting research that spanned multiple healthcare and research organizations, or networks. Finally, attendees considered public policy issues that would contribute to the long-term sustainability of such a national researchpractice ecosystem. (See Table 1 for questions presented to API2016 participants.) In preparation for the API2016, AMIA staff deployed a website 12 that supported preconference collaboration and discussion. Breakout session questions were posted 2 weeks in advance of the meeting, and participants were encouraged to engage with fellow attendees by considering the questions via discussion threads.
To supplement these discussions, API2016 attendees also heard keynotes given by National Library of Medicine Director Dr. Patricia Brennan, FDA Commissioner Dr. Robert Califf, and Agency for Healthcare Research and Quality Director Dr. Andrew Bindman. A summary of their remarks and links to their presentations can be found in Table 2 .
FINDINGS AND RECOMMENDATIONS
Key findings and recommendations from the meeting participants were captured, reviewed, categorized, and cataloged by the authors using an iterative, qualitative analytic approach that led to group consensus. The findings are summarized below. Recommendations for each set of findings are further detailed in Table 3 .
Nodes: policies needed to facilitate evidence generation at the local level
Finding: clinicians, patients, and health systems are not routinely engaged in research and often treat it as a separate component from care delivery. Focusing on enabling evidence-generation activities at the point-of-care as the most basic locus of research is vital because it represents a single, yet connected, node in a complex and integrated network Policy implication: incentives are needed for key stakeholders to prioritize research at the point-of-care-the nodes of an EGM system. Participating in certain research-related activities at the point-ofcare can involve an opportunity cost to clinicians and healthcare [13] [14] [15] [16] Further, these agencies have made strides in having patients and clinicians work together to fund, design, and implement research studies that address real-world questions that are important to patients. 17 However, to be effective, this trend must continue with the current Administration and Congress; steps should be taken to replicate this kind of engagement with both clinicians and health systems. Specifically, CMS should leverage its Quality Payment Program to reward clinical practice Improvement Activities (IAs) that involve research components. This would en-courage office-based physicians to invest time and resources needed to realize EGM. Further, federal agencies should develop funding priorities and special emphasis notices that encourage clinicians and health systems to collaborate in research studies and commit to share study results, in both raw data and curated formats, back to clinicians and patients. Practice-Based Research Networks (PBRNs) also remain a promising model for primary care clinicians and practices working together to answer community-based health questions and to translate those findings into practice. 18
Finding: current regulations present real and perceived barriers to evidence generation at the local level Policy implication: regulatory modifications are needed to facilitate research at the point-of-care. There is wide disparity in how current regulations governing informed consent and privacy protections are Generating Evidence to Inform Decisions in the Era of Precision Medicine 1. One big challenge in biomedicine is that we are missing the ability to measure the interactions of biology, sociology, environment, and organizational factors that could enable the individualization and optimization of care and improve population health. Although health and disease result from interactions of genes, derivative biological systems, environment, social context, and personal decisions, researchers often examine only one of these aspects. We are not collecting or analyzing the range of data needed to generate evidence needed to inform the health decisions that patients and their doctors make every day. 2. We must organize systems that can embed research into clinical practice. Common approaches for configuring, storing and reusing digital health data can enable the widespread participation in research required to generate the highquality evidence that is badly needed for therapeutic research, safety surveillance, public health, and quality improvement. 3. We need to train the workforce of the future provide and curate data using standards and terminology that support research and clinical care, collected by systems and interfaces that allow clinicians to spend more time with patients.
Robert Califf, MD, Commissioner, Food and Drug Administration
Building a Research Strategy to Support Learning Health Systems 1. Our health care system lags in its ability to adapt, affordably address patient needs, and consistently achieve better outcomes. We have the know-how and technology to substantially improve quality and reduce costs, but need to develop strategies that can be applied in dynamic and complex systems. 2. Health IT supports acquisition of data to provide measurement in real time, and find and analyze trends far faster than humans; and get needed information to clinicians at the point of care, when and where they need it. When systems are in place and incentives are aligned, IT can create a continuous feedback loop so that we are always learning-and that is the foundation of a learning health care system. 3. Practice-Based Research Networks (PBRNs) are ideal settings for studying the process of care and the manner in which diseases are diagnosed, treatments initiated, and chronic conditions managed in real-world settings. PBRNs provide opportunities to measure effectiveness and explore the interface between patients and their primary physicians.
Andy Bindman, MD, Director, Agency for Healthcare Research and Quality Finding: technical work on data standards and certified health IT functionality is needed to enable EGM and local learning health systems Policy implication: investment in the "basic science" of health IT, including supporting standards and processes for implementing and enhancing functional requirements, is necessary. Data standards are necessary to the exchange of clinical data and interoperability be-tween EHR systems will be critical for data aggregation and sharing. The development, harmonization, and use of standards for vocabulary, format, and transport will be essential for the continued improvement of health IT tools necessary to support EGM and LHS. While interoperability is an on-going challenge, agreement on standards is foundational to realizing the potential benefits of IT. As tools for care delivery, EHRs are not readily configured to facilitate EGM or supplemental uses of patient data for research, even when a patient explicitly wants to enable that use. IT tools that support the screening and recruitment of patients into research in the context of a healthcare encounter are needed, as are tools that enable patients to easily access their health data and transfer it to (share it with) research activities and investigations as they wish.
Networks: clinical research across organizations
The development of processes and systems to generate evidence at points-of-care (nodes) is an essential component of a LHS. [22] [23] [24] The value of research conducted at organizational nodes can be magnified when the nodes are integrated into networks. Networks of organizations, working in tandem, can leverage efficiencies of scale to include more clinicians and more patients in the generation of important knowledge, thereby mitigating common research challenges related to sufficient sample size, "representativeness" of sample populations, and the "generalizability" of study results. Research networks are of two types-regional (typically less than 5 organizations, often privately funded and geographically organized) and national-scale networks, which include a larger number of organizations, wider geographical distribution, and often rely on federal or foundation funding for large centralized infrastructure. The effectiveness of our national research networks is dependent on shared infrastructure that require appropriate levels of government support to complement initiatives from the private sector.
1. Federal funders should see an increasing proportion of their research portfolios as strategic investments rather than time-limited projects and coordinate them as such.
A. In order for the US to maintain its position as a leader in biomedical research, it must continue to prioritize large-scale cyberinfrastructure through dedicated funding. B. Federal investments in this infrastructure should take a long-term view, analogous to the concept of the National Science Foundation's Supercomputing Program, rather than a project-based view. The benefits of federally sponsored research must extend as much as possible beyond the awardees who conduct the research. (These national networks are described in Sustainability: maintaining a national research ecosystem section.) To identify the factors that enable regional and national research networks, API2016 participants organized into smaller breakout groups with targeted discussion on policy issues surrounding multisite research. Specifically, these groups discussed information flows to improve reproducibility, quality, veracity and completeness of data, and barriers to data sharing. A number of common themes emerged, falling into the familiar categories of people, process, and technology. Later, the breakout groups reconvened into the larger API2016 group to develop consensus findings on the major challenges for networked research, which are presented below.
Finding: the clinical and research workforce, including institutional review board (IRB) staff, data stewards, and data curators often lack a fundamental understanding of informatics-driven research methodologies Policy implication: informatics-driven research requires improved workforce competencies and federal support for informatics training. The healthcare and research enterprise envisioned for the 21st century will require a workforce competence beyond the mechanics of health IT and health information management. 7, 24 The API2016 participants identified three kinds of education and training that are necessary to EGM and the LHS: (1) basic "informatics literacy" for all health professionals incorporated with health practitioner education, [25] [26] [27] biomedical research training, 28 and public health education 29 ; (2) intensive applied informatics training for an additional cohort of practitioners to improve leadership and expertise in applying informatics principles to healthcare problems 30, 31 ; and (3) Support for informatics education professionals who will advance the science and train the next generation of informatics professionals. [32] [33] [34] "Informatics literacy" includes awareness of specific data standards and their importance to multisite research, the mechanics of data sharing, and the fulfillment of user needs that are specific to EBM, EGM, and learning cycles. Informatics professionals should be represented across all IRBs and grant selection committees where data sharing and informatics tools are part of the research.
Finally, a competent workforce for the future will depend upon federally funded recruitment and educational programs-targeted to high school, undergraduate, and professional students-that will encourage the next generation of health practitioners and researchers to engage in the science and practice of informatics. 35 This includes continuation of federal support for programs at the National Library of Medicine, 36 the Agency for Healthcare Research and Quality, 37 and Clinical Informatics Fellows funded through Graduate Medical Education. 38 Finding: incompatible data standards-including metadata and patient identifiers-and data use agreements create technical challenges and tremendous administrative burden on multisite research Policy implication: convergence of technical standards and governance can facilitate multi-site research and reduce legal burden. Organizations should be able to "consume" research findings from other organizations and networks (as part of their LHS mission) and share results with the broader community as EGM. This requires technical standards for data representation and exchange. [39] [40] [41] Regardless of whether they are in regional ad hoc research networks or part of nationally recognized research networks, health delivery organizations should be able to participate in multisite research, collaboration, and knowledge sharing. The development of a trusted exchange framework and common agreement, as required by the 21st Century Cures Act, 42 is meant to ease legal burdens to exchange clinical data for providers in treating patients. A similar mechanism should be spearheaded to help private-sector stakeholders share clinical data for research purposes, especially for small institutions that wish to contribute to research and participate in EGM, but are not part of PCORnet, 43 CTSA 44 or other national research networks. Such trust and collaboration frameworks can be informed by the experience of the NIH Health Care Systems Research Collaboratory, one part of the overall effort to improve the national capacity to generate evidence that informs healthcare decisions by patients, providers, and payers. 45, 46 Indeed, via a series of demonstration projects using a pragmatic research approach, Collaboratory investigators have shared lessons learned regarding the design, execution, and dissemination research conducted in partnership with multiple healthcare systems. 47 Among other recommendations, the Collaboratory EHR Core advocates for more federally driven (data) standards (to reduce the complexity and transformations required for multisite research) and policies to ensure that future electronic health record systems have the flexibility to support research, including implementation of new standardized data collection that fits into clinical workflows. 45, 46 Sustainability: maintaining a national research ecosystem Finding: the effectiveness of our national research networks will be dependent upon shared infrastructure requiring adequate support from the private sector and federal agencies Policy implication: federal funders should see an increasing proportion of their research portfolios as strategic investments rather than time-limited projects and coordinate them as such. Large scale infrastructure, supported by federal funding, is essential to the continued dominance of US biomedical research. This infrastructure includes both technology and the policies and procedures that enable best use of the technology. Federal investments in this infrastructure should take a long-term view, analogous to the concept of the National Science Foundation's Supercomputing Program, 48 rather than a project-based view, which places predetermined end points on federal support. Use of more agile funding mechanisms such Other Transaction Authority, and Cooperative Agreements, can help these programs work at the cutting edge of technology and be responsive to future needs in a rapidly changing environment.
Finding: the benefits of federally sponsored research must extend as much as possible beyond the awardees who conduct the research Policy implication: federal policy must improve the use of research data and the application of new knowledge for multiple stakeholders to derive value. Policies should target the reuse of data through improved data sharing plans and harmonized data management/ sharing policies across NIH institutions and centers. Similar policies could target reusability of biomedical knowledge that results from research studies, so this knowledge can be more readily applied to the improvement of health and care. Trans-NIH collaboration, as well as collaboration among other funding agencies, should compose a minimal percentage of the federal biomedical research portfolio so that research results can be more readily translated into practice. This concept should extend to the CMS, Veterans Health Administration and Defense Health Services, so that national-level research findings can be implemented at scale, as appropriate.
Finally, patients and families should be recognized as key stakeholders in our national research ecosystem, and they should be leveraged to enhance health IT systems for research, promote data standards, and help develop organizational research participation policies. 49 Patients and the public will ultimately be the beneficiaries of research, and they can promote the value of research through participation and driving research questions. Federal research funders should promote projects that leverage health informatics tools that enable patients and their families to participate in research as part of their healthcare experience whatever their geographical location, actively share their own health data with researchers of their choosing, and obtain the return of results of research in which they participate.
CONCLUSION
The AMIA 2016 Policy Invitational brought together informatics experts from across the spectrum of care and research with national policy leaders for a structured dialog designed to address barriers to EGM within the context of regional and national-level research and participants identified a number of possible solutions that could be supported by policy and advocacy. The findings of API2016 confirm that strategic co-ordination and co-operation on a national scale will be required in order to achieve safe and effective patient care amid continuous advances in medical knowledge and proliferation of HIT tools. As a multidisciplinary, multistakeholder organization representing more than 5400 members, AMIA appreciates the need for synergy between people, technology, and systems. Innovation and impact in care delivery and clinical research will depend on public policies that encourage collaboration, co-operation, and shared digital infrastructure.
In order to achieve the vision of nationally scaled evidencegenerating medicine where individual nodes contribute to larger networks and-ultimately-a sustainable LHS, national leadership, and investment is needed. Continued and increased funding for advanced health informatics training and cyberinfrastructure will be essential to ensure that biomedical research and EGM can be used to improve population health and healthcare delivery in the US. Without federal support to train clinicians and researchers on the fundamentals of health informatics literacy, we will fail to overcome current challenges and discover answers to important questions that face clinicians and patients. Further, without the cyberinfrastructure necessary to ask and answer clinical questions across disparate research networks, based on the best evidence-based knowledge and growing real-world data, we will not realize our vision of a LHS. The National Science Foundation has initiated important research in this area and NCATS has continued to fund large-scale projects. Moving forward, other agencies (eg AHRQ, ONC, CMS, CDC, and the VA) that would benefit from the promulgation of EGM should consider collaborative approaches to support the infrastructure required to generate evidence and implement findings more routinely and quickly.
Second, national policies should enable organizations to consume research findings from other organizations and networks easily, and share results with the broader community of healthcare and research practitioners. The development of trust frameworks, as required by the 21st Century Cures Act, is meant to ease legal burdens to exchange clinical data for providers in treating patients, so similar mechanisms should be spearheaded to help private-sector stakeholders share clinical data for research purposes, especially for small institutions who wish to contribute to research, but are not part of PCORnet, the CTSA program, or other national research networks. The NIH Collaboratory is vital resource for development of such processes and policies, and it should garner continued support from Congress and the White House. Additionally, revisions made to the Common Rule must be implemented in a co-ordinated fashion with the private sector, so that the benefits of these new changes can be realized across the country in consistent ways.
Finally, federal support is needed to ensure that better standards are developed and adopted in the private sector. Data standards are necessary to the exchange of clinical data and interoperability between health IT systems, are critical for data aggregation and sharing in research. The development, harmonization, and use of standards for vocabulary, format, and transport will be essential for the continued improvement of health IT tools necessary to support EGM and LHS. While interoperability is an on-going challenge, agreement on standards is foundational to realizing the potential of IT, and the federal government has important levers in certification and payment policies to help align private-sector adoption and use of health IT. The above recommendations will require the cooperation and engagement of many disciplines and stakeholders, but the return will have an impact on the costs of healthcare and biomedical research. Optimizing the use of health IT to support health care and research will create the infrastructure for LHS that ultimately can improve the lives of all Americans, now and into the future.
